Equities Analysts Offer Predictions for ADAP Q3 Earnings

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) – Research analysts at Leerink Partnrs boosted their Q3 2025 earnings per share estimates for shares of Adaptimmune Therapeutics in a research report issued to clients and investors on Wednesday, August 13th. Leerink Partnrs analyst J. Chang now expects that the biotechnology company will post earnings per share of ($0.05) for the quarter, up from their prior estimate of ($0.06). The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.14) per share. Leerink Partnrs also issued estimates for Adaptimmune Therapeutics’ Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.35) EPS and FY2026 earnings at ($0.01) EPS.

Several other analysts also recently weighed in on the stock. Guggenheim downgraded shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 29th. Wall Street Zen assumed coverage on Adaptimmune Therapeutics in a report on Friday, May 16th. They issued a “buy” rating on the stock. HC Wainwright reissued a “neutral” rating on shares of Adaptimmune Therapeutics in a research note on Tuesday, July 29th. Wells Fargo & Company reduced their price target on Adaptimmune Therapeutics from $1.50 to $1.00 and set an “equal weight” rating for the company in a report on Wednesday, May 14th. Finally, Mizuho lowered Adaptimmune Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $1.50 to $0.50 in a report on Thursday, June 26th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Adaptimmune Therapeutics has an average rating of “Hold” and an average price target of $1.35.

Adaptimmune Therapeutics Stock Performance

Shares of ADAP opened at $0.06 on Monday. The stock has a market capitalization of $15.77 million, a P/E ratio of -0.09 and a beta of 2.18. The company has a debt-to-equity ratio of 4.24, a quick ratio of 1.29 and a current ratio of 1.52. Adaptimmune Therapeutics has a 1 year low of $0.06 and a 1 year high of $1.33. The company’s fifty day moving average is $0.21 and its two-hundred day moving average is $0.31.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04. Adaptimmune Therapeutics had a negative return on equity of 163.73% and a negative net margin of 260.82%. The business had revenue of $13.68 million during the quarter, compared to analysts’ expectations of $11.04 million.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Institutional investors have recently modified their holdings of the company. Two Sigma Investments LP increased its stake in Adaptimmune Therapeutics by 33.5% in the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 19,146 shares in the last quarter. Invesco Ltd. grew its stake in Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 28,526 shares during the last quarter. Rock Springs Capital Management LP increased its holdings in Adaptimmune Therapeutics by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company’s stock valued at $1,338,000 after acquiring an additional 58,000 shares in the last quarter. Two Sigma Advisers LP increased its holdings in Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 58,787 shares in the last quarter. Finally, LPL Financial LLC raised its position in Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 94,623 shares during the last quarter. Hedge funds and other institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.